Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
7.27
+0.40 (5.90%)
At close: Apr 17, 2025, 4:00 PM
7.26
0.00 (-0.07%)
After-hours: Apr 17, 2025, 7:36 PM EDT
Intellia Therapeutics Stock Forecast
NTLA's stock price has decreased by -66.69% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Intellia Therapeutics stock have an average target of 39.44, with a low estimate of 11 and a high estimate of 90. The average target predicts an increase of 442.88% from the current stock price of 7.27.
Analyst Consensus: Buy
* Price targets were last updated on Mar 5, 2025.
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Hold | 5 | 5 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 18 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +312.94% | Mar 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $90 → $50 | Strong Buy | Maintains | $90 → $50 | +588.23% | Mar 4, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $26 | Buy | Maintains | $55 → $26 | +257.88% | Feb 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | +92.70% | Feb 28, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $60 → $50 | Buy | Maintains | $60 → $50 | +588.23% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
53.14M
from 57.88M
Decreased by -8.19%
Revenue Next Year
48.77M
from 53.14M
Decreased by -8.21%
EPS This Year
-4.75
from -5.25
EPS Next Year
-4.62
from -4.75
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 220.5M | 105.0M | 4.0B | ||
| Avg | 53.1M | 48.8M | 415.6M | ||
| Low | n/a | 6.9M | 3.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 281.0% | 97.6% | 8,052.1% | ||
| Avg | -8.2% | -8.2% | 752.2% | ||
| Low | - | -87.1% | -92.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.35 | -3.03 | -3.06 | ||
| Avg | -4.75 | -4.62 | -4.07 | ||
| Low | -5.60 | -5.56 | -5.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.